JAMES THOMAS BARKER
- Type
- Physician · Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Psychiatry
- Where
- HICKORY, NC
- NPI
- 1922189927
- Received
- $2,141,190 in 3,241 records, 2019 to 2025
- As principal investigator
- $1,944,753 of research payments to others in 318 records
- Source
- CMS Open Payments search ↗
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2025 | General payment | 641 | $508,882 |
| 2024 | General payment | 558 | $428,197 |
| 2023 | General payment | 551 | $372,558 |
| 2022 | General payment | 406 | $235,421 |
| 2021 | General payment | 380 | $189,724 |
| 2020 | General payment | 292 | $132,743 |
| 2019 | General payment | 413 | $273,662 |
By company
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a v | 674 | $1,665,760 |
| Consulting Fee | 69 | $191,503 |
| Travel and Lodging | 700 | $141,531 |
| Honoraria | 24 | $81,002 |
| Food and Beverage | 1,769 | $61,325 |
| Education | 5 | $67 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2025-12-30 | E.R. Squibb & Sons, L.L.C. | $1,661 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | COBENFY Drug, Neuroscience | 2025 | |
| 2025-12-23 | E.R. Squibb & Sons, L.L.C. | $18 | Food and Beverage | Cash or cash equivalent | COBENFY Drug, Neuroscience | 2025 | |
| 2025-12-23 | E.R. Squibb & Sons, L.L.C. | $9 | Food and Beverage | Cash or cash equivalent | COBENFY Drug, Neuroscience | 2025 | |
| 2025-12-22 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,220 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | CAPLYTA Drug, PSYCHIATRY | 2025 | |
| 2025-12-18 | Janssen Pharmaceuticals, Inc | $915 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | INVEGA SUSTENNA Drug, Neuroscience | 2025 | |
| 2025-12-18 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $126 | Food and Beverage | In-kind items and services | CAPLYTA Drug, PSYCHIATRY | 2025 | |
| 2025-12-18 | Bausch Health US, LLC | $18 | Food and Beverage | In-kind items and services | APLENZIN Drug, Neurology | 2025 | |
| 2025-12-18 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $14 | Food and Beverage | In-kind items and services | CAPLYTA Drug, PSYCHIATRY | 2025 | |
| 2025-12-18 | Corium, LLC | $6 | Food and Beverage | In-kind items and services | Azstarys Drug, CNS Stimulant for ADHD | 2025 | |
| 2025-12-18 | Neurocrine BioSciences, Inc. | $4 | Food and Beverage | In-kind items and services | INGREZZA Drug, Neuropsychiatry | 2025 | |
| 2025-12-16 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $26 | Food and Beverage | In-kind items and services | CAPLYTA Drug, PSYCHIATRY | 2025 | |
| 2025-12-16 | Alkermes, Inc. | $24 | Food and Beverage | In-kind items and services | ARISTADA Drug, CNS | 2025 | |
| 2025-12-16 | Vanda Pharmaceuticals Inc. | $8 | Food and Beverage | In-kind items and services | FANAPT Drug, SCHIZOPHRENIA | 2025 | |
| 2025-12-15 | E.R. Squibb & Sons, L.L.C. | $23 | Travel and Lodging | Cash or cash equivalent | COBENFY Drug, Neuroscience | 2025 | |
| 2025-12-12 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $4,440 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | CAPLYTA Drug, PSYCHIATRY | 2025 | |
| 2025-12-12 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,220 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | CAPLYTA Drug, PSYCHIATRY | 2025 | |
| 2025-12-11 | Neurocrine BioSciences, Inc. | $42 | Food and Beverage | In-kind items and services | INGREZZA Drug, Neuropsychiatry | 2025 | |
| 2025-12-10 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $4,440 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | CAPLYTA Drug, PSYCHIATRY | 2025 | |
| 2025-12-10 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $24 | Food and Beverage | In-kind items and services | CAPLYTA Drug, PSYCHIATRY | 2025 | |
| 2025-12-08 | Alkermes, Inc. | $17 | Food and Beverage | In-kind items and services | ARISTADA Drug, CNS | 2025 | |
| 2025-12-04 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,775 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | CAPLYTA Drug, PSYCHIATRY | 2025 | |
| 2025-12-04 | E.R. Squibb & Sons, L.L.C. | $140 | Travel and Lodging | Cash or cash equivalent | COBENFY Drug, Neuroscience | 2025 | |
| 2025-12-04 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $22 | Food and Beverage | In-kind items and services | CAPLYTA Drug, PSYCHIATRY | 2025 | |
| 2025-12-04 | Axsome Therapeutics, Inc. | $15 | Food and Beverage | In-kind items and services | Auvelity Drug, Psychology/Psychiatric | 2025 | |
| 2025-12-03 | E.R. Squibb & Sons, L.L.C. | $55 | Food and Beverage | Cash or cash equivalent | COBENFY Drug, Neuroscience | 2025 | |
| 2025-12-03 | E.R. Squibb & Sons, L.L.C. | $6 | Food and Beverage | Cash or cash equivalent | COBENFY Drug, Neuroscience | 2025 | |
| 2025-12-03 | E.R. Squibb & Sons, L.L.C. | $2 | Food and Beverage | Cash or cash equivalent | COBENFY Drug, Neuroscience | 2025 | |
| 2025-12-01 | Otsuka America Pharmaceutical, Inc. | $26 | Food and Beverage | In-kind items and services | REXULTI Drug, PSYCHIATRY | 2025 | |
| 2025-11-26 | Neurocrine BioSciences, Inc. | $6,468 | Consulting Fee | Cash or cash equivalent | INGREZZA Drug, Neuropsychiatry | 2025 | |
| 2025-11-26 | E.R. Squibb & Sons, L.L.C. | $2,215 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | COBENFY Drug, Neuroscience | 2025 | |
| 2025-11-26 | Neurocrine BioSciences, Inc. | $110 | Travel and Lodging | In-kind items and services | INGREZZA Drug, Neuropsychiatry | 2025 | |
| 2025-11-25 | E.R. Squibb & Sons, L.L.C. | $3,876 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | COBENFY Drug, Neuroscience | 2025 | |
| 2025-11-25 | Alkermes, Inc. | $19 | Food and Beverage | In-kind items and services | ARISTADA Drug, CNS | 2025 | |
| 2025-11-20 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,220 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | CAPLYTA Drug, PSYCHIATRY | 2025 | |
| 2025-11-20 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $31 | Food and Beverage | In-kind items and services | CAPLYTA Drug, PSYCHIATRY | 2025 | |
| 2025-11-20 | Axsome Therapeutics, Inc. | $15 | Food and Beverage | In-kind items and services | Auvelity Drug, Psychology/Psychiatric | 2025 | |
| 2025-11-20 | Neurocrine BioSciences, Inc. | $10 | Food and Beverage | In-kind items and services | INGREZZA Drug, Neuropsychiatry | 2025 | |
| 2025-11-19 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $17 | Food and Beverage | In-kind items and services | CAPLYTA Drug, PSYCHIATRY | 2025 | |
| 2025-11-18 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $6 | Food and Beverage | In-kind items and services | CAPLYTA Drug, PSYCHIATRY | 2025 | |
| 2025-11-17 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $4,440 | Consulting Fee | Cash or cash equivalent | CAPLYTA Drug, PSYCHIATRY | 2025 | |
| 2025-11-17 | E.R. Squibb & Sons, L.L.C. | $20 | Food and Beverage | Cash or cash equivalent | COBENFY Drug, Neuroscience | 2025 | |
| 2025-11-17 | E.R. Squibb & Sons, L.L.C. | $6 | Food and Beverage | Cash or cash equivalent | COBENFY Drug, Neuroscience | 2025 | |
| 2025-11-13 | E.R. Squibb & Sons, L.L.C. | $108 | Food and Beverage | Cash or cash equivalent | COBENFY Drug, Neuroscience | 2025 | |
| 2025-11-13 | E.R. Squibb & Sons, L.L.C. | $10 | Travel and Lodging | Cash or cash equivalent | COBENFY Drug, Neuroscience | 2025 | |
| 2025-11-12 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $207 | Travel and Lodging | In-kind items and services | CAPLYTA Drug, PSYCHIATRY | 2025 | |
| 2025-11-12 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $114 | Food and Beverage | In-kind items and services | CAPLYTA Drug, PSYCHIATRY | 2025 | |
| 2025-11-12 | Takeda Pharmaceuticals U.S.A., Inc. | $15 | Food and Beverage | In-kind items and services | TRINTELLIX Drug, NEUROSCIENCE | 2025 | |
| 2025-11-12 | Axsome Therapeutics, Inc. | $14 | Food and Beverage | In-kind items and services | Auvelity Drug, Psychology/Psychiatric | 2025 | |
| 2025-11-11 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $4,440 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | CAPLYTA Drug, PSYCHIATRY | 2025 | |
| 2025-11-11 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $143 | Travel and Lodging | In-kind items and services | CAPLYTA Drug, PSYCHIATRY | 2025 | |
| 2025-11-11 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $54 | Food and Beverage | In-kind items and services | CAPLYTA Drug, PSYCHIATRY | 2025 | |
| 2025-11-10 | Vanda Pharmaceuticals Inc. | $28 | Food and Beverage | In-kind items and services | FANAPT Drug, SCHIZOPHRENIA | 2025 | |
| 2025-11-07 | E.R. Squibb & Sons, L.L.C. | $4,430 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | COBENFY Drug, Neuroscience | 2025 | |
| 2025-11-07 | Neurocrine BioSciences, Inc. | $9 | Food and Beverage | In-kind items and services | INGREZZA Drug, Neuropsychiatry | 2025 | |
| 2025-11-06 | Axsome Therapeutics, Inc. | $2,025 | Honoraria | Cash or cash equivalent | Auvelity Drug, Psychology/Psychiatric | 2025 | |
| 2025-11-06 | Axsome Therapeutics, Inc. | $240 | Travel and Lodging | Cash or cash equivalent | Auvelity Drug, Psychology/Psychiatric | 2025 | |
| 2025-11-06 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $123 | Food and Beverage | In-kind items and services | CAPLYTA Drug, PSYCHIATRY | 2025 | |
| 2025-11-05 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $3,885 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | CAPLYTA Drug, PSYCHIATRY | 2025 | |
| 2025-11-05 | Axsome Therapeutics, Inc. | $3,375 | Honoraria | Cash or cash equivalent | Auvelity Drug, Psychology/Psychiatric | 2025 | |
| 2025-11-05 | Axsome Therapeutics, Inc. | $705 | Travel and Lodging | In-kind items and services | Auvelity Drug, Psychology/Psychiatric | 2025 | |
| 2025-11-05 | Axsome Therapeutics, Inc. | $172 | Travel and Lodging | Cash or cash equivalent | Auvelity Drug, Psychology/Psychiatric | 2025 | |
| 2025-11-05 | Axsome Therapeutics, Inc. | $54 | Food and Beverage | Cash or cash equivalent | Auvelity Drug, Psychology/Psychiatric | 2025 | |
| 2025-11-04 | Supernus Pharmaceuticals, Inc. | $23 | Food and Beverage | In-kind items and services | Qelbree Drug, VILOXAZINE HYDROCHLORIDE | 2025 | |
| 2025-11-04 | Axsome Therapeutics, Inc. | $19 | Food and Beverage | In-kind items and services | Auvelity Drug, Psychology/Psychiatric | 2025 | |
| 2025-11-03 | Neurocrine BioSciences, Inc. | $918 | Travel and Lodging | In-kind items and services | INGREZZA Drug, Neuropsychiatry | 2025 | |
| 2025-11-03 | Neurocrine BioSciences, Inc. | $395 | Travel and Lodging | In-kind items and services | INGREZZA Drug, Neuropsychiatry | 2025 | |
| 2025-11-03 | Neurocrine BioSciences, Inc. | $265 | Travel and Lodging | In-kind items and services | INGREZZA Drug, Neuropsychiatry | 2025 | |
| 2025-11-03 | Neurocrine BioSciences, Inc. | $122 | Travel and Lodging | In-kind items and services | INGREZZA Drug, Neuropsychiatry | 2025 | |
| 2025-11-03 | Neurocrine BioSciences, Inc. | $51 | Food and Beverage | In-kind items and services | INGREZZA Drug, Neuropsychiatry | 2025 | |
| 2025-11-03 | Neurocrine BioSciences, Inc. | $41 | Travel and Lodging | In-kind items and services | INGREZZA Drug, Neuropsychiatry | 2025 | |
| 2025-11-03 | Neurocrine BioSciences, Inc. | $41 | Travel and Lodging | In-kind items and services | INGREZZA Drug, Neuropsychiatry | 2025 | |
| 2025-11-03 | Neurocrine BioSciences, Inc. | $34 | Food and Beverage | In-kind items and services | INGREZZA Drug, Neuropsychiatry | 2025 | |
| 2025-11-03 | Neurocrine BioSciences, Inc. | $34 | Food and Beverage | In-kind items and services | INGREZZA Drug, Neuropsychiatry | 2025 | |
| 2025-11-03 | Neurocrine BioSciences, Inc. | $17 | Food and Beverage | In-kind items and services | INGREZZA Drug, Neuropsychiatry | 2025 | |
| 2025-11-03 | Neurocrine BioSciences, Inc. | $17 | Food and Beverage | In-kind items and services | INGREZZA Drug, Neuropsychiatry | 2025 | |
| 2025-11-02 | Neurocrine BioSciences, Inc. | $162 | Food and Beverage | In-kind items and services | INGREZZA Drug, Neuropsychiatry | 2025 | |
| 2025-10-30 | Axsome Therapeutics, Inc. | $3,375 | Honoraria | Cash or cash equivalent | Auvelity Drug, Psychology/Psychiatric | 2025 | |
| 2025-10-30 | Axsome Therapeutics, Inc. | $240 | Travel and Lodging | Cash or cash equivalent | Auvelity Drug, Psychology/Psychiatric | 2025 | |
| 2025-10-30 | Bausch Health US, LLC | $3 | Food and Beverage | In-kind items and services | APLENZIN Drug, Neurology | 2025 | |
| 2025-10-29 | Alkermes, Inc. | $3,820 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | LYBALVI Drug, CNS | 2025 | |
| 2025-10-29 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,775 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | CAPLYTA Drug, PSYCHIATRY | 2025 | |
| 2025-10-29 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,220 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | CAPLYTA Drug, PSYCHIATRY | 2025 | |
| 2025-10-29 | Axsome Therapeutics, Inc. | $2,025 | Honoraria | Cash or cash equivalent | Auvelity Drug, Psychology/Psychiatric | 2025 | |
| 2025-10-29 | Alkermes, Inc. | $252 | Travel and Lodging | In-kind items and services | LYBALVI Drug, CNS | 2025 | |
| 2025-10-29 | Alkermes, Inc. | $248 | Travel and Lodging | In-kind items and services | LYBALVI Drug, CNS | 2025 | |
| 2025-10-29 | Axsome Therapeutics, Inc. | $93 | Travel and Lodging | Cash or cash equivalent | Auvelity Drug, Psychology/Psychiatric | 2025 | |
| 2025-10-29 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $85 | Travel and Lodging | Cash or cash equivalent | CAPLYTA Drug, PSYCHIATRY | 2025 | |
| 2025-10-29 | Axsome Therapeutics, Inc. | $40 | Travel and Lodging | Cash or cash equivalent | Auvelity Drug, Psychology/Psychiatric | 2025 | |
| 2025-10-29 | Alkermes, Inc. | $32 | Food and Beverage | In-kind items and services | LYBALVI Drug, CNS | 2025 | |
| 2025-10-29 | Alkermes, Inc. | $32 | Travel and Lodging | In-kind items and services | LYBALVI Drug, CNS | 2025 | |
| 2025-10-29 | Axsome Therapeutics, Inc. | $26 | Food and Beverage | Cash or cash equivalent | Auvelity Drug, Psychology/Psychiatric | 2025 | |
| 2025-10-29 | Axsome Therapeutics, Inc. | $16 | Travel and Lodging | Cash or cash equivalent | Auvelity Drug, Psychology/Psychiatric | 2025 | |
| 2025-10-29 | Axsome Therapeutics, Inc. | $4 | Travel and Lodging | Cash or cash equivalent | Auvelity Drug, Psychology/Psychiatric | 2025 | |
| 2025-10-28 | Axsome Therapeutics, Inc. | $3,375 | Honoraria | Cash or cash equivalent | Auvelity Drug, Psychology/Psychiatric | 2025 | |
| 2025-10-28 | Axsome Therapeutics, Inc. | $387 | Travel and Lodging | In-kind items and services | Auvelity Drug, Psychology/Psychiatric | 2025 | |
| 2025-10-28 | Axsome Therapeutics, Inc. | $273 | Travel and Lodging | In-kind items and services | Auvelity Drug, Psychology/Psychiatric | 2025 | |
| 2025-10-28 | Axsome Therapeutics, Inc. | $135 | Travel and Lodging | Cash or cash equivalent | Auvelity Drug, Psychology/Psychiatric | 2025 | |
| 2025-10-28 | Axsome Therapeutics, Inc. | $67 | Food and Beverage | Cash or cash equivalent | Auvelity Drug, Psychology/Psychiatric | 2025 | |
| 2025-10-28 | Bausch Health US, LLC | $25 | Food and Beverage | In-kind items and services | APLENZIN Drug, Neurology | 2025 | |
| 2025-10-28 | Axsome Therapeutics, Inc. | $25 | Travel and Lodging | Cash or cash equivalent | Auvelity Drug, Psychology/Psychiatric | 2025 | |
| 2025-10-28 | Axsome Therapeutics, Inc. | $12 | Food and Beverage | In-kind items and services | Auvelity Drug, Psychology/Psychiatric | 2025 | |
| 2025-10-28 | Axsome Therapeutics, Inc. | $10 | Food and Beverage | In-kind items and services | Auvelity Drug, Psychology/Psychiatric | 2025 | |
| 2025-10-27 | Luye Pharma (USA) Ltd. | $27 | Food and Beverage | In-kind items and services | ERZOFRI EXTENDED-RELEASE Drug, Treatment of schizophrenia and schizoaffective disorder in adults | 2025 | |
| 2025-10-27 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $19 | Food and Beverage | In-kind items and services | CAPLYTA Drug, PSYCHIATRY | 2025 | |
| 2025-10-23 | E.R. Squibb & Sons, L.L.C. | $3,322 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | COBENFY Drug, Neuroscience | 2025 | |
| 2025-10-22 | Axsome Therapeutics, Inc. | $3,375 | Honoraria | Cash or cash equivalent | Auvelity Drug, Psychology/Psychiatric | 2025 | |
| 2025-10-22 | Axsome Therapeutics, Inc. | $267 | Travel and Lodging | In-kind items and services | Auvelity Drug, Psychology/Psychiatric | 2025 | |
| 2025-10-22 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $238 | Travel and Lodging | In-kind items and services | CAPLYTA Drug, PSYCHIATRY | 2025 | |
| 2025-10-22 | Axsome Therapeutics, Inc. | $150 | Travel and Lodging | Cash or cash equivalent | Auvelity Drug, Psychology/Psychiatric | 2025 | |
| 2025-10-22 | Axsome Therapeutics, Inc. | $148 | Travel and Lodging | Cash or cash equivalent | Auvelity Drug, Psychology/Psychiatric | 2025 | |
| 2025-10-22 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $105 | Food and Beverage | In-kind items and services | CAPLYTA Drug, PSYCHIATRY | 2025 | |
| 2025-10-22 | Axsome Therapeutics, Inc. | $58 | Food and Beverage | Cash or cash equivalent | Auvelity Drug, Psychology/Psychiatric | 2025 | |
| 2025-10-21 | Axsome Therapeutics, Inc. | $4,388 | Honoraria | Cash or cash equivalent | Auvelity Drug, Psychology/Psychiatric | 2025 | |
| 2025-10-21 | Axsome Therapeutics, Inc. | $3,375 | Honoraria | Cash or cash equivalent | Auvelity Drug, Psychology/Psychiatric | 2025 | |
| 2025-10-21 | Axsome Therapeutics, Inc. | $175 | Travel and Lodging | Cash or cash equivalent | Auvelity Drug, Psychology/Psychiatric | 2025 | |
| 2025-10-21 | Axsome Therapeutics, Inc. | $147 | Travel and Lodging | Cash or cash equivalent | Auvelity Drug, Psychology/Psychiatric | 2025 | |
| 2025-10-21 | Axsome Therapeutics, Inc. | $92 | Food and Beverage | In-kind items and services | Auvelity Drug, Psychology/Psychiatric | 2025 | |
| 2025-10-21 | Axsome Therapeutics, Inc. | $41 | Food and Beverage | Cash or cash equivalent | Auvelity Drug, Psychology/Psychiatric | 2025 | |
| 2025-10-21 | Axsome Therapeutics, Inc. | $18 | Food and Beverage | In-kind items and services | Auvelity Drug, Psychology/Psychiatric | 2025 | |
| 2025-10-20 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $23 | Food and Beverage | In-kind items and services | CAPLYTA Drug, PSYCHIATRY | 2025 | |
| 2025-10-20 | Axsome Therapeutics, Inc. | $17 | Food and Beverage | In-kind items and services | Auvelity Drug, Psychology/Psychiatric | 2025 | |
| 2025-10-16 | Axsome Therapeutics, Inc. | $24 | Food and Beverage | In-kind items and services | Auvelity Drug, Psychology/Psychiatric | 2025 | |
| 2025-10-15 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $129 | Food and Beverage | In-kind items and services | CAPLYTA Drug, PSYCHIATRY | 2025 | |
| 2025-10-15 | Vanda Pharmaceuticals Inc. | $25 | Food and Beverage | In-kind items and services | FANAPT Drug, SCHIZOPHRENIA | 2025 | |
| 2025-10-14 | Neurocrine BioSciences, Inc. | $24 | Food and Beverage | In-kind items and services | INGREZZA Drug, Neuropsychiatry | 2025 | |
| 2025-10-14 | Otsuka America Pharmaceutical, Inc. | $11 | Food and Beverage | In-kind items and services | REXULTI Drug, PSYCHIATRY | 2025 | |
| 2025-10-13 | Takeda Pharmaceuticals U.S.A., Inc. | $15 | Food and Beverage | In-kind items and services | TRINTELLIX Drug, NEUROSCIENCE | 2025 | |
| 2025-10-08 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $22 | Food and Beverage | In-kind items and services | CAPLYTA Drug, PSYCHIATRY | 2025 | |
| 2025-10-07 | Supernus Pharmaceuticals, Inc. | $23 | Food and Beverage | In-kind items and services | Qelbree Drug, VILOXAZINE HYDROCHLORIDE | 2025 | |
| 2025-10-06 | Otsuka America Pharmaceutical, Inc. | $21 | Food and Beverage | In-kind items and services | REXULTI Drug, PSYCHIATRY | 2025 | |
| 2025-10-04 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $275 | Travel and Lodging | In-kind items and services | CAPLYTA Drug, PSYCHIATRY | 2025 | |
| 2025-10-04 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $138 | Food and Beverage | In-kind items and services | CAPLYTA Drug, PSYCHIATRY | 2025 | |
| 2025-10-04 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $59 | Food and Beverage | In-kind items and services | CAPLYTA Drug, PSYCHIATRY | 2025 | |
| 2025-10-04 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $52 | Food and Beverage | In-kind items and services | CAPLYTA Drug, PSYCHIATRY | 2025 | |
| 2025-10-04 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $48 | Travel and Lodging | In-kind items and services | CAPLYTA Drug, PSYCHIATRY | 2025 | |
| 2025-10-04 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $46 | Food and Beverage | In-kind items and services | CAPLYTA Drug, PSYCHIATRY | 2025 | |
| 2025-10-04 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $24 | Food and Beverage | In-kind items and services | CAPLYTA Drug, PSYCHIATRY | 2025 | |
| 2025-10-04 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $24 | Food and Beverage | In-kind items and services | CAPLYTA Drug, PSYCHIATRY | 2025 | |
| 2025-10-03 | Alkermes, Inc. | $2,290 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | ARISTADA Drug, CNS | 2025 | |
| 2025-10-02 | Otsuka America Pharmaceutical, Inc. | $109 | Travel and Lodging | Cash or cash equivalent | REXULTI Drug, PSYCHIATRY | 2025 | |
| 2025-10-02 | Otsuka America Pharmaceutical, Inc. | $20 | Food and Beverage | Cash or cash equivalent | REXULTI Drug, PSYCHIATRY | 2025 | |
| 2025-10-01 | Axsome Therapeutics, Inc. | $19 | Food and Beverage | In-kind items and services | Auvelity Drug, Psychology/Psychiatric | 2025 | |
| 2025-09-30 | Axsome Therapeutics, Inc. | $1,350 | Honoraria | Cash or cash equivalent | Auvelity Drug, Psychology/Psychiatric | 2025 | |
| 2025-09-30 | Lilly USA, LLC | $19 | Food and Beverage | In-kind items and services | AMYVID Drug, Neuroscience | 2025 | |
| 2025-09-29 | Teva Pharmaceuticals USA, Inc. | $21 | Food and Beverage | In-kind items and services | UZEDY Drug, Neurology | 2025 | |
| 2025-09-26 | Janssen Pharmaceuticals, Inc | $3,885 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | INVEGA SUSTENNA Drug, Neuroscience | 2025 | |
| 2025-09-26 | Janssen Pharmaceuticals, Inc | $150 | Food and Beverage | In-kind items and services | INVEGA SUSTENNA Drug, Neuroscience | 2025 | |
| 2025-09-25 | Janssen Pharmaceuticals, Inc | $310 | Travel and Lodging | In-kind items and services | INVEGA SUSTENNA Drug, Neuroscience | 2025 | |
| 2025-09-23 | Axsome Therapeutics, Inc. | $4,725 | Honoraria | Cash or cash equivalent | Auvelity Drug, Psychology/Psychiatric | 2025 | |
| 2025-09-23 | Axsome Therapeutics, Inc. | $3,038 | Honoraria | Cash or cash equivalent | Auvelity Drug, Psychology/Psychiatric | 2025 | |
| 2025-09-23 | Axsome Therapeutics, Inc. | $213 | Travel and Lodging | Cash or cash equivalent | Auvelity Drug, Psychology/Psychiatric | 2025 | |
| 2025-09-23 | Axsome Therapeutics, Inc. | $212 | Travel and Lodging | Cash or cash equivalent | Auvelity Drug, Psychology/Psychiatric | 2025 | |
| 2025-09-23 | Axsome Therapeutics, Inc. | $119 | Food and Beverage | In-kind items and services | Auvelity Drug, Psychology/Psychiatric | 2025 | |
| 2025-09-23 | Axsome Therapeutics, Inc. | $60 | Food and Beverage | Cash or cash equivalent | Auvelity Drug, Psychology/Psychiatric | 2025 | |
| 2025-09-23 | Axsome Therapeutics, Inc. | $23 | Food and Beverage | Cash or cash equivalent | Auvelity Drug, Psychology/Psychiatric | 2025 | |
| 2025-09-23 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $23 | Food and Beverage | In-kind items and services | CAPLYTA Drug, PSYCHIATRY | 2025 | |
| 2025-09-23 | Axsome Therapeutics, Inc. | $11 | Travel and Lodging | Cash or cash equivalent | Auvelity Drug, Psychology/Psychiatric | 2025 | |
| 2025-09-20 | Otsuka America Pharmaceutical, Inc. | $3,078 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | REXULTI Drug, PSYCHIATRY | 2025 | |
| 2025-09-19 | Otsuka America Pharmaceutical, Inc. | $14 | Food and Beverage | In-kind items and services | REXULTI Drug, PSYCHIATRY | 2025 | |
| 2025-09-18 | Neurocrine BioSciences, Inc. | $49 | Food and Beverage | In-kind items and services | INGREZZA Drug, Neuropsychiatry | 2025 | |
| 2025-09-17 | Alkermes, Inc. | $27 | Food and Beverage | In-kind items and services | ARISTADA Drug, CNS | 2025 | |
| 2025-09-16 | Bausch Health US, LLC | $23 | Food and Beverage | In-kind items and services | APLENZIN Drug, Neurology | 2025 | |
| 2025-09-16 | Bausch Health US, LLC | $7 | Food and Beverage | In-kind items and services | APLENZIN Drug, Neurology | 2025 | |
| 2025-09-15 | Neurocrine BioSciences, Inc. | $24 | Food and Beverage | In-kind items and services | INGREZZA Drug, Neuropsychiatry | 2025 | |
| 2025-09-09 | Supernus Pharmaceuticals, Inc. | $24 | Food and Beverage | In-kind items and services | Qelbree Drug, VILOXAZINE HYDROCHLORIDE | 2025 | |
| 2025-09-08 | Otsuka America Pharmaceutical, Inc. | $25 | Food and Beverage | In-kind items and services | REXULTI Drug, PSYCHIATRY | 2025 | |
| 2025-09-03 | Alkermes, Inc. | $3,820 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | LYBALVI Drug, CNS | 2025 | |
| 2025-09-03 | Alkermes, Inc. | $2,100 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | LYBALVI Drug, CNS | 2025 | |
| 2025-09-03 | Alkermes, Inc. | $2,100 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | LYBALVI Drug, CNS | 2025 | |
| 2025-09-03 | Alkermes, Inc. | $332 | Travel and Lodging | In-kind items and services | LYBALVI Drug, CNS | 2025 | |
| 2025-09-03 | Alkermes, Inc. | $282 | Travel and Lodging | In-kind items and services | LYBALVI Drug, CNS | 2025 | |
| 2025-09-03 | Alkermes, Inc. | $134 | Travel and Lodging | In-kind items and services | ARISTADA Drug, CNS | 2025 | |
| 2025-09-03 | Alkermes, Inc. | $58 | Food and Beverage | In-kind items and services | LYBALVI Drug, CNS | 2025 | |
| 2025-09-03 | Alkermes, Inc. | $51 | Travel and Lodging | In-kind items and services | LYBALVI Drug, CNS | 2025 | |
| 2025-09-03 | Alkermes, Inc. | $33 | Food and Beverage | In-kind items and services | LYBALVI Drug, CNS | 2025 | |
| 2025-09-03 | Alkermes, Inc. | $18 | Travel and Lodging | In-kind items and services | LYBALVI Drug, CNS | 2025 | |
| 2025-08-28 | Janssen Pharmaceuticals, Inc | $1,220 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | SPRAVATO Drug, Neuroscience | 2025 | |
| 2025-08-28 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $19 | Food and Beverage | In-kind items and services | CAPLYTA Drug, PSYCHIATRY | 2025 | |
| 2025-08-28 | Janssen Pharmaceuticals, Inc | $5 | Travel and Lodging | In-kind items and services | INVEGA SUSTENNA Drug, Neuroscience | 2025 | |
| 2025-08-27 | Teva Pharmaceuticals USA, Inc. | $19 | Food and Beverage | In-kind items and services | AUSTEDO XR Drug, Central Nervous System | 2025 | |
| 2025-08-26 | Neurocrine BioSciences, Inc. | $4,600 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | INGREZZA Drug, Neuropsychiatry | 2025 | |
| 2025-08-26 | Neurocrine BioSciences, Inc. | $215 | Travel and Lodging | In-kind items and services | INGREZZA Drug, Neuropsychiatry | 2025 | |
| 2025-08-26 | Neurocrine BioSciences, Inc. | $23 | Food and Beverage | In-kind items and services | INGREZZA Drug, Neuropsychiatry | 2025 | |
| 2025-08-26 | Neurocrine BioSciences, Inc. | $21 | Food and Beverage | In-kind items and services | INGREZZA Drug, Neuropsychiatry | 2025 | |
| 2025-08-25 | Neurocrine BioSciences, Inc. | $4,600 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | INGREZZA Drug, Neuropsychiatry | 2025 | |
| 2025-08-25 | Neurocrine BioSciences, Inc. | $126 | Travel and Lodging | In-kind items and services | INGREZZA Drug, Neuropsychiatry | 2025 | |
| 2025-08-21 | Janssen Pharmaceuticals, Inc | $27 | Food and Beverage | In-kind items and services | SPRAVATO Drug, Neuroscience | 2025 | |
| 2025-08-20 | Alkermes, Inc. | $246 | Travel and Lodging | In-kind items and services | LYBALVI Drug, CNS | 2025 | |
| 2025-08-20 | Alkermes, Inc. | $184 | Travel and Lodging | In-kind items and services | LYBALVI Drug, CNS | 2025 | |
| 2025-08-20 | Alkermes, Inc. | $113 | Food and Beverage | In-kind items and services | LYBALVI Drug, CNS | 2025 | |
| 2025-08-20 | Alkermes, Inc. | $48 | Food and Beverage | In-kind items and services | LYBALVI Drug, CNS | 2025 | |
| 2025-08-20 | Alkermes, Inc. | $31 | Food and Beverage | In-kind items and services | LYBALVI Drug, CNS | 2025 | |
| 2025-08-19 | Alkermes, Inc. | $288 | Travel and Lodging | In-kind items and services | LYBALVI Drug, CNS | 2025 | |
| 2025-08-19 | Alkermes, Inc. | $123 | Food and Beverage | In-kind items and services | LYBALVI Drug, CNS | 2025 | |
| 2025-08-19 | E.R. Squibb & Sons, L.L.C. | $53 | Travel and Lodging | Cash or cash equivalent | COBENFY Drug, Neuroscience | 2025 | |
| 2025-08-19 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2 | Food and Beverage | In-kind items and services | CAPLYTA Drug, PSYCHIATRY | 2025 | |
| 2025-08-18 | Neurocrine BioSciences, Inc. | $4,600 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | INGREZZA Drug, Neuropsychiatry | 2025 | |
| 2025-08-18 | Neurocrine BioSciences, Inc. | $137 | Travel and Lodging | In-kind items and services | INGREZZA Drug, Neuropsychiatry | 2025 | |
| 2025-08-18 | Neurocrine BioSciences, Inc. | $19 | Food and Beverage | In-kind items and services | INGREZZA Drug, Neuropsychiatry | 2025 | |
| 2025-08-14 | Axsome Therapeutics, Inc. | $16 | Food and Beverage | In-kind items and services | Auvelity Drug, Psychology/Psychiatric | 2025 |
The latest 200 records of 3,241.
Research payments naming this person as principal investigator
| Date | Company | Paid to | Amount | Study | Year |
|---|---|---|---|---|---|
| 2025-12-29 | Janssen Research & Development, LLC | IM SUPER HOLDINGS LLC | $380 | A Two-Part Multicenter, Double-Blind, Randomized Placebo-Controlled Study to Evaluate Efficacy and Safety and the Mainte | 2025 |
| 2025-12-11 | Janssen Research & Development, LLC | IM SUPER HOLDINGS LLC | $140 | A Two-Part Multicenter, Double-Blind, Randomized Placebo-Controlled Study to Evaluate Efficacy and Safety and the Mainte | 2025 |
| 2025-12-11 | Axsome Therapeutics, Inc. | IMA Clinical Research, Hickory, North Carolina | $531 | A Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms | 2025 |
| 2025-12-11 | Axsome Therapeutics, Inc. | IMA Clinical Research, Hickory, North Carolina | $3,764 | A Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms | 2025 |
| 2025-12-04 | Janssen Research & Development, LLC | IM SUPER HOLDINGS LLC | $262 | A Two-Part Multicenter, Double-Blind, Randomized Placebo-Controlled Study to Evaluate Efficacy and Safety and the Mainte | 2025 |
| 2025-11-14 | Axsome Therapeutics, Inc. | IMA Clinical Research, Hickory, North Carolina | $5,666 | A Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms | 2025 |
| 2025-10-17 | Axsome Therapeutics, Inc. | IMA Clinical Research, Hickory, North Carolina | $531 | A Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms | 2025 |
| 2025-10-17 | Axsome Therapeutics, Inc. | IMA Clinical Research, Hickory, North Carolina | $5,254 | A Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms | 2025 |
| 2025-10-09 | Sumitomo Pharma America, Inc. | IM SUPER HOLDINGS LLC | $2,750 | AN 8-WEEK, OPEN-LABEL STUDY EVALUATING THE EFFECTIVENESS, SAFETY AND TOLERABILITY OF SEP-363856 IN SUBJECTS WITH SCHIZOP | 2025 |
| 2025-10-09 | Sumitomo Pharma America, Inc. | IM SUPER HOLDINGS LLC | $1,290 | AN 8-WEEK, OPEN-LABEL STUDY EVALUATING THE EFFECTIVENESS, SAFETY AND TOLERABILITY OF SEP-363856 IN SUBJECTS WITH SCHIZOP | 2025 |
| 2025-10-09 | Sumitomo Pharma America, Inc. | IM SUPER HOLDINGS LLC | $900 | AN 8-WEEK, OPEN-LABEL STUDY EVALUATING THE EFFECTIVENESS, SAFETY AND TOLERABILITY OF SEP-363856 IN SUBJECTS WITH SCHIZOP | 2025 |
| 2025-10-03 | Janssen Research & Development, LLC | IM SUPER HOLDINGS LLC | $9,907 | A Two-Part Multicenter, Double-Blind, Randomized Placebo-Controlled Study to Evaluate Efficacy and Safety and the Mainte | 2025 |
| 2025-09-15 | Axsome Therapeutics, Inc. | IMA Clinical Research, Hickory, North Carolina | $4,779 | A Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms | 2025 |
| 2025-09-11 | Sumitomo Pharma America, Inc. | IM SUPER HOLDINGS LLC | $3,025 | A 24-WEEK, OPEN-LABEL STUDY EVALUATING THE EFFECTIVENESS, SAFETY AND TOLERABILITY OF SEP-363856 IN SUBJECTS WITH SCHIZOP | 2025 |
| 2025-08-13 | Axsome Therapeutics, Inc. | IMA Clinical Research, Hickory, North Carolina | $6,089 | A Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms | 2025 |
| 2025-07-31 | Janssen Research & Development, LLC | IM SUPER HOLDINGS LLC | $22,500 | A Two-Part Multicenter, Double-Blind, Randomized Placebo-Controlled Study to Evaluate Efficacy and Safety and the Mainte | 2025 |
| 2025-07-23 | Axsome Therapeutics, Inc. | IMA Clinical Research, Hickory, North Carolina | $5,453 | A Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms | 2025 |
| 2025-07-23 | Axsome Therapeutics, Inc. | IMA Clinical Research, Hickory, North Carolina | $500 | A Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms | 2025 |
| 2025-06-13 | Axsome Therapeutics, Inc. | IMA Clinical Research, Hickory, North Carolina | $31 | A Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms | 2025 |
| 2025-06-13 | Axsome Therapeutics, Inc. | IMA Clinical Research, Hickory, North Carolina | $6,543 | A Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms | 2025 |
| 2025-05-16 | Axsome Therapeutics, Inc. | IMA Clinical Research, Hickory, North Carolina | $554 | A Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms | 2025 |
| 2025-05-16 | Axsome Therapeutics, Inc. | IMA Clinical Research, Hickory, North Carolina | $9,046 | A Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms | 2025 |
| 2025-04-16 | Axsome Therapeutics, Inc. | IMA Clinical Research, Hickory, North Carolina | $108 | A Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms | 2025 |
| 2025-04-11 | Sumitomo Pharma America, Inc. | Ima Evaluations Llc | $40 | A 24-WEEK, OPEN-LABEL STUDY EVALUATING THE EFFECTIVENESS, SAFETY AND TOLERABILITY OF SEP-363856 IN SUBJECTS WITH SCHIZOP | 2025 |
| 2025-03-24 | Axsome Therapeutics, Inc. | IMA Clinical Research, Hickory, North Carolina | $500 | A Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms | 2025 |
| 2025-03-21 | Sumitomo Pharma America, Inc. | Ima Evaluations Llc | $1,973 | A 24-WEEK, OPEN-LABEL STUDY EVALUATING THE EFFECTIVENESS, SAFETY AND TOLERABILITY OF SEP-363856 IN SUBJECTS WITH SCHIZOP | 2025 |
| 2025-03-03 | Sumitomo Pharma America, Inc. | Ima Evaluations Llc | $148 | A 24-WEEK, OPEN-LABEL STUDY EVALUATING THE EFFECTIVENESS, SAFETY AND TOLERABILITY OF SEP-363856 IN SUBJECTS WITH SCHIZOP | 2025 |
| 2025-02-18 | Axsome Therapeutics, Inc. | IMA Clinical Research, Hickory, North Carolina | $2,048 | A Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms | 2025 |
| 2025-02-14 | Axsome Therapeutics, Inc. | IMA Clinical Research, Hickory, North Carolina | $500 | A Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms | 2025 |
| 2025-01-28 | Sumitomo Pharma America, Inc. | Ima Evaluations Llc | $1,290 | A 24-WEEK, OPEN-LABEL STUDY EVALUATING THE EFFECTIVENESS, SAFETY AND TOLERABILITY OF SEP-363856 IN SUBJECTS WITH SCHIZOP | 2025 |
| 2025-01-28 | Sumitomo Pharma America, Inc. | Ima Evaluations Llc | $8,500 | A 24-WEEK, OPEN-LABEL STUDY EVALUATING THE EFFECTIVENESS, SAFETY AND TOLERABILITY OF SEP-363856 IN SUBJECTS WITH SCHIZOP | 2025 |
| 2025-01-22 | Sumitomo Pharma America, Inc. | Ima Evaluations Llc | $650 | A 24-WEEK, OPEN-LABEL STUDY EVALUATING THE EFFECTIVENESS, SAFETY AND TOLERABILITY OF SEP-363856 IN SUBJECTS WITH SCHIZOP | 2025 |
| 2025-01-22 | Sumitomo Pharma America, Inc. | Ima Evaluations Llc | $3,500 | A 24-WEEK, OPEN-LABEL STUDY EVALUATING THE EFFECTIVENESS, SAFETY AND TOLERABILITY OF SEP-363856 IN SUBJECTS WITH SCHIZOP | 2025 |
| 2025-01-15 | E.R. Squibb & Sons, L.L.C. | The Ima Group | $67,005 | An Extension Study to Assess Long-Term Safety and Tolerability of Adjunctive KarXT in Subjects With Inadequately Control | 2025 |
| 2025-01-06 | E.R. Squibb & Sons, L.L.C. | The Ima Group | $46,670 | A Study to Assess Efficacy and Safety of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of Schizophr | 2025 |
| 2024-12-23 | Axsome Therapeutics, Inc. | IM SUPER HOLDINGS LLC | $2,048 | A Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms | 2024 |
| 2024-11-06 | E.R. Squibb & Sons, L.L.C. | The Ima Group | $26,898 | Phase III OLE of KarXT in Adjuct Schiz (ARISE 2) - An Extension Study to Assess Long-Term Safety and Tolerability of Adj | 2024 |
| 2024-09-27 | E.R. Squibb & Sons, L.L.C. | The Ima Group | $12,333 | Phase III Efficacy and Safety of KarXT in Adjuct Schiz (ARISE 1) | 2024 |
| 2024-09-19 | Supernus Pharmaceuticals, Inc. | IM Super Holdings LLC dba IMA Evaluations LLC | $250 | A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of NV-513 | 2024 |
| 2024-09-12 | Supernus Pharmaceuticals, Inc. | IM Super Holdings LLC dba IMA Evaluations LLC | $2,155 | A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of NV-513 | 2024 |
| 2024-09-10 | Axsome Therapeutics, Inc. | IM SUPER HOLDINGS LLC | $554 | A Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms | 2024 |
| 2024-08-07 | Supernus Pharmaceuticals, Inc. | IM Super Holdings LLC dba IMA Evaluations LLC | $1,972 | A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of NV-513 | 2024 |
| 2024-07-25 | Supernus Pharmaceuticals, Inc. | IM Super Holdings LLC dba IMA Evaluations LLC | $17,628 | A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of NV-513 | 2024 |
| 2024-07-16 | Axsome Therapeutics, Inc. | IM SUPER HOLDINGS LLC | $3,691 | A Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms | 2024 |
| 2024-07-16 | Axsome Therapeutics, Inc. | IM SUPER HOLDINGS LLC | $500 | A Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms | 2024 |
| 2024-07-11 | Supernus Pharmaceuticals, Inc. | IM Super Holdings LLC dba IMA Evaluations LLC | $13,157 | A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of NV-513 | 2024 |
| 2024-06-20 | Axsome Therapeutics, Inc. | IM SUPER HOLDINGS LLC | $1,162 | A Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms | 2024 |
| 2024-06-20 | Supernus Pharmaceuticals, Inc. | IM Super Holdings LLC dba IMA Evaluations LLC | $5,814 | A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of NV-513 | 2024 |
| 2024-06-20 | Axsome Therapeutics, Inc. | IM SUPER HOLDINGS LLC | $5,453 | A Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms | 2024 |
| 2024-05-16 | Axsome Therapeutics, Inc. | IM SUPER HOLDINGS LLC | $5,933 | A Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms | 2024 |
| 2024-04-19 | E.R. Squibb & Sons, L.L.C. | The Ima Group | $36,788 | An Extension Study to Assess Long-Term Safety and Tolerability of Adjunctive KarXT in Subjects With Inadequately Control | 2024 |
| 2024-04-16 | Axsome Therapeutics, Inc. | IM SUPER HOLDINGS LLC | $4,288 | A Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms | 2024 |
| 2024-04-10 | Supernus Pharmaceuticals, Inc. | IM Super Holdings LLC dba IMA Evaluations LLC | $1,500 | A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of NV-513 | 2024 |
| 2024-03-29 | Sumitomo Pharma America, Inc. | Clinical Trials of America LLC | $70 | A Clinical Study That Will Evaluate How Well SEP-363856 Works and How Safe it is in People With Schizophrenia That Switc | 2024 |
| 2024-03-18 | Axsome Therapeutics, Inc. | IM SUPER HOLDINGS LLC | $2,432 | A Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms | 2024 |
| 2024-03-15 | Sumitomo Pharma America, Inc. | Ima Evaluations Llc | $2,227 | A Clinical Study That Will Evaluate How Well SEP-363856 Works and How Safe it is in People With Schizophrenia That Switc | 2024 |
| 2024-03-15 | Sumitomo Pharma America, Inc. | Ima Evaluations Llc | $880 | A Clinical Study That Will Evaluate How Well SEP-363856 Works and How Safe it is in People With Schizophrenia That Switc | 2024 |
| 2024-03-13 | Sumitomo Pharma America, Inc. | Ima Evaluations Llc | $11,445 | A Clinical Study That Will Evaluate How Well SEP-363856 Works and How Safe it is in People With Schizophrenia That Switc | 2024 |
| 2024-03-08 | Sumitomo Pharma America, Inc. | Ima Evaluations Llc | $7,832 | An Extension Study to a Clinical Study That Will Continue to Evaluate the Effectiveness and Safety of SEP-363856 in Peop | 2024 |
| 2024-03-05 | Sumitomo Pharma America, Inc. | Clinical Trials of America LLC | $0 | A Clinical Study That Will Evaluate How Well SEP-363856 Works and How Safe it is in People With Schizophrenia That Switc | 2024 |
| 2024-03-05 | Sumitomo Pharma America, Inc. | Clinical Trials of America LLC | $1 | A Clinical Study That Will Evaluate How Well SEP-363856 Works and How Safe it is in People With Schizophrenia That Switc | 2024 |
| 2024-03-05 | Sumitomo Pharma America, Inc. | Clinical Trials of America LLC | $4 | A Clinical Study That Will Evaluate How Well SEP-363856 Works and How Safe it is in People With Schizophrenia That Switc | 2024 |
| 2024-03-05 | Sumitomo Pharma America, Inc. | Clinical Trials of America LLC | $6 | A Clinical Study That Will Evaluate How Well SEP-363856 Works and How Safe it is in People With Schizophrenia That Switc | 2024 |
| 2024-03-05 | Sumitomo Pharma America, Inc. | Clinical Trials of America LLC | $0 | A Clinical Study That Will Evaluate How Well SEP-363856 Works and How Safe it is in People With Schizophrenia That Switc | 2024 |
| 2024-03-05 | Sumitomo Pharma America, Inc. | Clinical Trials of America LLC | $46 | A Clinical Study That Will Evaluate How Well SEP-363856 Works and How Safe it is in People With Schizophrenia That Switc | 2024 |
| 2024-02-29 | Sumitomo Pharma America, Inc. | Clinical Trials of America LLC | $70 | A Clinical Study That Will Evaluate How Well SEP-363856 Works and How Safe it is in People With Schizophrenia That Switc | 2024 |
| 2024-02-27 | Axsome Therapeutics, Inc. | IM SUPER HOLDINGS LLC | $7,500 | A Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms | 2024 |
| 2024-02-22 | Supernus Pharmaceuticals, Inc. | IM Super Holdings LLC dba IMA Evaluations LLC | $15,500 | A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of NV-513 | 2024 |
| 2024-02-14 | Sumitomo Pharma America, Inc. | Ima Evaluations Llc | $750 | An Extension Study to a Clinical Study That Will Continue to Evaluate the Effectiveness and Safety of SEP-363856 in Peop | 2024 |
| 2024-02-14 | Sumitomo Pharma America, Inc. | Ima Evaluations Llc | $21,132 | An Extension Study to a Clinical Study That Will Continue to Evaluate the Effectiveness and Safety of SEP-363856 in Peop | 2024 |
| 2024-02-14 | Sumitomo Pharma America, Inc. | Ima Evaluations Llc | $196 | An Extension Study to a Clinical Study That Will Continue to Evaluate the Effectiveness and Safety of SEP-363856 in Peop | 2024 |
| 2024-02-14 | Sumitomo Pharma America, Inc. | Ima Evaluations Llc | $650 | An Extension Study to a Clinical Study That Will Continue to Evaluate the Effectiveness and Safety of SEP-363856 in Peop | 2024 |
| 2024-02-14 | Sumitomo Pharma America, Inc. | Ima Evaluations Llc | $650 | An Extension Study to a Clinical Study That Will Continue to Evaluate the Effectiveness and Safety of SEP-363856 in Peop | 2024 |
| 2024-02-14 | Sumitomo Pharma America, Inc. | Ima Evaluations Llc | $5,500 | An Extension Study to a Clinical Study That Will Continue to Evaluate the Effectiveness and Safety of SEP-363856 in Peop | 2024 |
| 2024-02-14 | Sumitomo Pharma America, Inc. | Ima Evaluations Llc | $490 | An Extension Study to a Clinical Study That Will Continue to Evaluate the Effectiveness and Safety of SEP-363856 in Peop | 2024 |
| 2024-02-09 | Sumitomo Pharma America, Inc. | Ima Evaluations Llc | $32,638 | A Clinical Study That Will Evaluate How Well SEP-363856 Works and How Safe it is in People With Schizophrenia That Switc | 2024 |
| 2024-02-07 | Sumitomo Pharma America, Inc. | Ima Evaluations Llc | $11,777 | An Extension Study to a Clinical Study That Will Continue to Evaluate the Effectiveness and Safety of SEP-363856 in Peop | 2024 |
| 2024-02-01 | Sumitomo Pharma America, Inc. | Clinical Trials of America LLC | $42 | A Clinical Study That Will Evaluate How Well SEP-363856 Works and How Safe it is in People With Schizophrenia That Switc | 2024 |
| 2024-02-01 | Sumitomo Pharma America, Inc. | Clinical Trials of America LLC | $37 | A Clinical Study That Will Evaluate How Well SEP-363856 Works and How Safe it is in People With Schizophrenia That Switc | 2024 |
| 2024-02-01 | Sumitomo Pharma America, Inc. | Clinical Trials of America LLC | $6 | A Clinical Study That Will Evaluate How Well SEP-363856 Works and How Safe it is in People With Schizophrenia That Switc | 2024 |
| 2024-02-01 | Sumitomo Pharma America, Inc. | Clinical Trials of America LLC | $8 | A Clinical Study That Will Evaluate How Well SEP-363856 Works and How Safe it is in People With Schizophrenia That Switc | 2024 |
| 2024-01-31 | Sumitomo Pharma America, Inc. | Clinical Trials of America LLC | $70 | A Clinical Study That Will Evaluate How Well SEP-363856 Works and How Safe it is in People With Schizophrenia That Switc | 2024 |
| 2024-01-10 | Sumitomo Pharma America, Inc. | Ima Evaluations Llc | $26,901 | An Extension Study to a Clinical Study That Will Continue to Evaluate the Effectiveness and Safety of SEP-363856 in Peop | 2024 |
| 2024-01-10 | Sumitomo Pharma America, Inc. | Ima Evaluations Llc | $28,969 | A Clinical Study That Will Evaluate How Well SEP-363856 Works and How Safe it is in People With Schizophrenia That Switc | 2024 |
| 2024-01-04 | Sumitomo Pharma America, Inc. | Clinical Trials of America LLC | $165 | A Clinical Study That Will Evaluate How Well SEP-363856 Works and How Safe it is in People With Schizophrenia That Switc | 2024 |
| 2024-01-04 | Sumitomo Pharma America, Inc. | Clinical Trials of America LLC | $8 | A Clinical Study That Will Evaluate How Well SEP-363856 Works and How Safe it is in People With Schizophrenia That Switc | 2024 |
| 2024-01-04 | Sumitomo Pharma America, Inc. | Clinical Trials of America LLC | $16 | A Clinical Study That Will Evaluate How Well SEP-363856 Works and How Safe it is in People With Schizophrenia That Switc | 2024 |
| 2024-01-04 | Sumitomo Pharma America, Inc. | Clinical Trials of America LLC | $6 | A Clinical Study That Will Evaluate How Well SEP-363856 Works and How Safe it is in People With Schizophrenia That Switc | 2024 |
| 2024-01-04 | Sumitomo Pharma America, Inc. | Clinical Trials of America LLC | $295 | A Clinical Study That Will Evaluate How Well SEP-363856 Works and How Safe it is in People With Schizophrenia That Switc | 2024 |
| 2023-12-29 | Sumitomo Pharma America, Inc. | Clinical Trials of America. LLC | $70 | A Clinical Study That Will Evalute How Well SEP-363856 Works and How Safe it is in People With Schizophrenia That Switch | 2023 |
| 2023-12-04 | Sumitomo Pharma America, Inc. | Clinical Trials of America LLC | $15 | A Clinical Study That Will Evalute How Well SEP-363856 Works and How Safe it is in People With Schizophrenia That Switch | 2023 |
| 2023-12-04 | Sumitomo Pharma America, Inc. | Ima Evaluations Llc | $5,294 | A Clinical Study That Will Evalute How Well SEP-363856 Works and How Safe it is in People With Schizophrenia That Switch | 2023 |
| 2023-12-04 | Sumitomo Pharma America, Inc. | Ima Evaluations Llc | $1,661 | A 24-Week Open-Label Study Evaluating the Effectiveness Safety and Tolerability of SEP-363856 in Subjects with Schizophr | 2023 |
| 2023-12-04 | Sumitomo Pharma America, Inc. | Ima Evaluations Llc | $1,661 | A 24-Week Open-Label Study Evaluating the Effectiveness Safety and Tolerability of SEP-363856 in Subjects with Schizophr | 2023 |
| 2023-12-04 | Sumitomo Pharma America, Inc. | Ima Evaluations Llc | $1,661 | A 24-Week Open-Label Study Evaluating the Effectiveness Safety and Tolerability of SEP-363856 in Subjects with Schizophr | 2023 |
| 2023-12-04 | Sumitomo Pharma America, Inc. | Ima Evaluations Llc | $1,661 | A 24-Week Open-Label Study Evaluating the Effectiveness Safety and Tolerability of SEP-363856 in Subjects with Schizophr | 2023 |
| 2023-12-04 | Sumitomo Pharma America, Inc. | Ima Evaluations Llc | $1,661 | A 24-Week Open-Label Study Evaluating the Effectiveness Safety and Tolerability of SEP-363856 in Subjects with Schizophr | 2023 |
| 2023-12-04 | Sumitomo Pharma America, Inc. | Ima Evaluations Llc | $1,661 | A 24-Week Open-Label Study Evaluating the Effectiveness Safety and Tolerability of SEP-363856 in Subjects with Schizophr | 2023 |
| 2023-12-04 | Sumitomo Pharma America, Inc. | Ima Evaluations Llc | $1,661 | A 24-Week Open-Label Study Evaluating the Effectiveness Safety and Tolerability of SEP-363856 in Subjects with Schizophr | 2023 |
| 2023-12-04 | Sumitomo Pharma America, Inc. | Ima Evaluations Llc | $1,661 | A 24-Week Open-Label Study Evaluating the Effectiveness Safety and Tolerability of SEP-363856 in Subjects with Schizophr | 2023 |
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Hickory, NC, county Catawba County, NC, state North Carolina; placed by its city name.
| Measure | Place (city or town) Hickory, NC | County Catawba County, NC | State North Carolina |
|---|---|---|---|
| Population B01003 | 44,258 | 163,573 | 10,730,404 |
| Population, 2020 census P1 | 43,490 | 160,610 | 10,439,388 |
| Median age B01002 | 37.5 | 42.1 | 39.1 |
| Under 18 B01001 | 21.3% | 21.6% | 21.8% |
| 65 and over B01001 | 17.1% | 18.7% | 17.2% |
| Households B11001 | 18,042 | 66,227 | 4,282,345 |
| Foreign born B05002 | 9.6% | 6.9% | 9.1% |
| Median household income B19013 | $64,576 | $67,864 | $72,388 |
| Median family income B19113 | $81,001 | $81,362 | $90,290 |
| Per capita income B19301 | $38,101 | $37,462 | $41,385 |
| Poverty rate B17001 | 17.1% | 12.7% | 13.0% |
| Unemployment rate B23025 | 3.8% | 3.7% | 4.7% |
| Civilian labor force B23025 | 21,430 | 80,216 | 5,336,863 |
| Mean commute (minutes) B08013 | 21.1 | 23.4 | 25.1 |
| Bachelor's degree or higher B15003 | 37.1% | 26.1% | 35.7% |
| Housing units B25001 | 19,955 | 73,133 | 4,895,668 |
| Owner-occupied B25003 | 55.0% | 72.2% | 66.6% |
| Renters B25003 | 45.0% | 27.8% | 33.4% |
| Median home value B25077 | $278,400 | $241,600 | $288,900 |
| Median gross rent B25064 | $1,063 | $965 | $1,228 |
| White, not Hispanic B03002 | 62.6% | 71.9% | 60.0% |
| Black B03002 | 13.0% | 7.7% | 20.0% |
| Hispanic or Latino B03002 | 15.2% | 11.5% | 11.3% |
| Asian B03002 | 4.8% | 4.3% | 3.3% |
| American Indian and Alaska Native B03002 | 0.1% | 0.1% | 0.8% |
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Hickory, NC.
Comments